Figure 1
![Type I IFN-activated signaling pathways. The type I IFN can be activated by different signaling cascades: JAK-STAT, MAPK [8], PI3K-NFκB or alternative NFκB. JAK-STAT activation leads to the ISGs induction via tyrosine phosphorylation of the STAT1 and STAT1-STAT2 complex. STATs dimer is transported to the nucleus to create a complex with IRF9 transcription factor and bind to ISRE. NFκB activation may occur via phosphorylation of Akt and IKKβ or TRAF and IKKα. Other signaling pathway activates three MAP kinases: p38, JNK, ERK](https://sciendo-parsed.s3.eu-central-1.amazonaws.com/647088b271e4585e08a9f607/j_ahem-2021-0001_fig_001.jpg?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Credential=AKIA6AP2G7AKOUXAVR44%2F20251105%2Feu-central-1%2Fs3%2Faws4_request&X-Amz-Date=20251105T234935Z&X-Amz-Expires=3600&X-Amz-Signature=bbf4fa9a4da0ecf049464dea8fadde9b9d316965e5d9bf850001071ed7269618&X-Amz-SignedHeaders=host&x-amz-checksum-mode=ENABLED&x-id=GetObject)
Type I interferon therapies of multiple sclerosis and hepatitis C virus infection
By:
Figures & Tables
DOI: https://doi.org/10.2478/ahem-2021-0001 | Journal eISSN: 1732-2693
Language: English
Page range: 537 - 547
Submitted on: Nov 16, 2020
Accepted on: Apr 23, 2021
Published on: Oct 21, 2021
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Related subjects:
© 2021 Izabella Jasyk, Jakub Siednienko, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.